Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis.

IF 2.8 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-05-29 DOI:10.1080/17474086.2026.2680141

Jing Wang, Dongming Zhou, Chenglan Lv, Min Zhou, Rongfu Zhou, Yuan Wan

{"title":"Primary diffuse large B-cell lymphoma in the era of targeted therapies: incidence, second primary malignancy and prognosis.","authors":"Jing Wang, Dongming Zhou, Chenglan Lv, Min Zhou, Rongfu Zhou, Yuan Wan","doi":"10.1080/17474086.2026.2680141","DOIUrl":null,"url":null,"abstract":"Background: To comprehensively illustrate the status of primary diffuse large B-cell lymphoma (DLBCL) in the era of targeted therapies.Research design and methods: Data from patients who were newly diagnosed with primary DLBCL from 2000 to 2021 in SEER 17 Registry Database were analyzed. The incidence and occurrence of second primary malignancies (SPM) and the prognosis of DLBCL were identified.Results: A total of 106,501 DLBCL patients were included. The median age at diagnosis was 66.0 years, and the disease was more prevalent in male and white patients. The age-standardized incidence rate in 2021 was 5.6 per 100,000, showing a significant decrease (average annual percent change of -0.43%) from 2002 to 2021. The risk of developing any SPM among DLBCL survivors was approximately 30% higher than that in the general population (95% confidence interval (CI): 1.28-1.33, p < 0.05). Significant risk factors for SPMs included the male sex (hazard ratio (HR) = 1.21, 95% CI: 1.16-1.27) and a diagnosis after 2009 (HR = 1.25, 95% CI: 1.20-1.31).Conclusions: The incidence of DLBCL has slightly decreased, whereas the risk of SPM has increased. The prognosis has improved, likely because of targeted therapies. Further investigation is warranted to refine treatment strategies and reduce the SPM risk.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"957-965"},"PeriodicalIF":2.8000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2026.2680141","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To comprehensively illustrate the status of primary diffuse large B-cell lymphoma (DLBCL) in the era of targeted therapies.

Research design and methods: Data from patients who were newly diagnosed with primary DLBCL from 2000 to 2021 in SEER 17 Registry Database were analyzed. The incidence and occurrence of second primary malignancies (SPM) and the prognosis of DLBCL were identified.

Results: A total of 106,501 DLBCL patients were included. The median age at diagnosis was 66.0 years, and the disease was more prevalent in male and white patients. The age-standardized incidence rate in 2021 was 5.6 per 100,000, showing a significant decrease (average annual percent change of -0.43%) from 2002 to 2021. The risk of developing any SPM among DLBCL survivors was approximately 30% higher than that in the general population (95% confidence interval (CI): 1.28-1.33, p < 0.05). Significant risk factors for SPMs included the male sex (hazard ratio (HR) = 1.21, 95% CI: 1.16-1.27) and a diagnosis after 2009 (HR = 1.25, 95% CI: 1.20-1.31).

Conclusions: The incidence of DLBCL has slightly decreased, whereas the risk of SPM has increased. The prognosis has improved, likely because of targeted therapies. Further investigation is warranted to refine treatment strategies and reduce the SPM risk.

查看原文本刊更多论文

靶向治疗时代的原发性弥漫性大b细胞淋巴瘤：发病率、第二原发恶性和预后。

背景：全面阐述原发性弥漫性大b细胞淋巴瘤（DLBCL）在靶向治疗时代的现状。研究设计和方法：分析SEER 17注册数据库2000 - 2021年新诊断的原发性DLBCL患者的数据。确定了DLBCL的第二原发恶性肿瘤（SPM）的发生率和发生情况以及预后。结果：共纳入106501例DLBCL患者。诊断时的中位年龄为66.0岁，该病在男性和白人患者中更为普遍。2021年年龄标准化发病率为5.6 / 10万，从2002年到2021年显著下降（年均变化率为-0.43%）。DLBCL幸存者发生任何SPM的风险比一般人群高出约30%（95%置信区间（CI）： 1.28-1.33, p）。结论：DLBCL的发病率略有下降，而SPM的风险有所增加。预后有所改善，可能是因为有针对性的治疗。需要进一步研究以完善治疗策略并降低SPM风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.